Alpha Tau Medical Stock (NASDAQ:DRTS)


ForecastOwnershipFinancialsChart

Previous Close

$2.30

52W Range

$1.75 - $3.40

50D Avg

$2.29

200D Avg

$2.53

Market Cap

$156.63M

Avg Vol (3M)

$22.95K

Beta

0.78

Div Yield

-

DRTS Company Profile


Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

121

IPO Date

Mar 08, 2021

Website

DRTS Performance


DRTS Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-35.68M$-32.14M$-13.79M
Net Income$-29.16M$-33.76M$-27.27M
EBITDA$-34.61M$-32.14M$-13.79M
Basic EPS$-0.42$-0.53$-0.40
Diluted EPS$-0.42$-0.53$-0.40

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
TNYATenaya Therapeutics, Inc.
OCULOcular Therapeutix, Inc.
CSBRChampions Oncology, Inc.
ERYPPHAXIAM Therapeutics S.A.
INZYInozyme Pharma, Inc.
HCWBHCW Biologics Inc.
EYENEyenovia, Inc.
MNOVMediciNova, Inc.
GNFTGenfit S.A.
MOLNMolecular Partners AG
ELYMEliem Therapeutics, Inc.